Lacrat (Ticagrelor)

• Ticagrelor is used in the management of platelet‑driven cardiovascular conditions.
• Acute coronary syndrome: reduces the risk of cardiovascular death, myocardial infarction and stroke.
• Myocardial infarction: prevents recurrent ischemic events after an acute heart attack.
• Prevention of thrombotic cardiovascular events: lowers the incidence of clot‑related complications in high‑risk patients.

• Ticagrelor acts as a reversible antagonist of the platelet P2Y12 ADP receptor. By binding to this receptor it blocks ADP‑mediated activation of the GPIIb/IIIa complex, thereby inhibiting platelet aggregation and thrombus formation without requiring metabolic activation.

Ticagrelor may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Dyspnea: shortness of breath, often transient.
• Bleeding: including bruising, nosebleeds, or gastrointestinal bleeding.
• Headache: mild to moderate intensity.
• Nausea or dyspepsia: gastrointestinal discomfort.
• Dizziness or vertigo: sensation of light‑headedness.
• Elevated serum uric acid: may precipitate gout in susceptible individuals.

Serious or Rare Side Effects

• Severe or life‑threatening bleeding: intracranial or fatal hemorrhage.
• Thrombocytopenia: marked reduction in platelet count.
• Anaphylactic or severe hypersensitivity reactions.
• Hepatic injury: elevated transaminases or liver dysfunction.
• Bradyarrhythmias: unusually slow heart rate.
• Hyperkalemia: elevated blood potassium levels.

Before prescribing Ticagrelor, clinicians should consider several safety aspects.

• Assess bleeding risk: evaluate history of hemorrhage, recent surgery or trauma.
• Monitor renal function: dose adjustment may be needed in severe impairment.
• Review concomitant antithrombotic therapy: avoid unnecessary combination with other anticoagulants.
• Caution in patients with a history of asthma or COPD: dyspnea may be exacerbated.
• Avoid use in patients with active pathological bleeding.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Ticagrelor interacts with several drug classes that can modify its antiplatelet effect or increase bleeding risk.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise ticagrelor plasma levels.
• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy.
• Concurrent anticoagulants (warfarin, DOACs): markedly increase bleeding.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs, aspirin): additive bleeding risk.
• Glycoprotein IIb/IIIa inhibitors: potentiate antiplatelet activity.

Moderate Interactions (Monitor Closely)

• Statins metabolised by CYP3A4 (e.g., atorvastatin, simvastatin): may increase statin exposure.
• Digoxin: ticagrelor can raise digoxin concentrations.
• Calcium channel blockers (e.g., amlodipine): may modestly increase ticagrelor levels.
• Proton pump inhibitors: potential effect on absorption, monitor efficacy.